ReviewApplied microbiology and biotechnology2020
Recent advances and new strategies in Leishmaniasis diagnosis.
Review in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 55 citations in OpenAlex.
- Evaluating the stability of antibody titres against Leishmania infantum determined by IFAT in long-term stored canine frozen samples.Parasites & vectors · 2025Article
- Nanobiosensors for revolutionizing parasitic infections diagnosis: a critical review to improve global health with an update on future challenges prospect.European journal of medical research · 2025Review
- Can Wastewater Surveillance Enhance Genomic Tracking of Climate-Driven Pathogens?Microorganisms · 2025Review
- Exploring the Potential of Malvidin and Echiodinin as Probable Antileishmanial Agents Through In Silico Analysis and In Vitro Efficacy.Molecules (Basel, Switzerland) · 2025Article
- Metagenomic next-generation sequencing assists in the diagnosis of visceral leishmaniasis in non-endemic areas of China.Frontiers in cellular and infection microbiology · 2025Article
- A Presumptive Case of Mucocutaneous and Visceral Leishmaniasis in Nonendemic Country.Clinical, cosmetic and investigational dermatology · 2025Article
- Evaluation of the Antigenic Potential of Epitopes Derived FromBioinformatics and biology insights · 2025Article
- Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review.Molecules (Basel, Switzerland) · 2024Review
- Serological Screening and Risk Factors Associated withMicroorganisms · 2024Article
- A deep learning-based model for detecting Leishmania amastigotes in microscopic slides: a new approach to telemedicine.BMC infectious diseases · 2024Article
- Synthetic Peptides Selected by Immunoinformatics as Potential Tools for the Specific Diagnosis of Canine Visceral Leishmaniasis.Microorganisms · 2024Article
- Overview of Research on Leishmaniasis in Africa: Current Status, Diagnosis, Therapeutics, and Recent Advances Using By-Products of the Sargassaceae Family.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Diagnosis of Canine Visceral Leishmaniasis by Flow Cytometry Serology using the rMELEISH Multiepitope Antigen Coupled in a Functional Bead.Current pharmaceutical biotechnology · 2024Article
- Scoping Review of Deep Learning Techniques for Diagnosis, Drug Discovery, and Vaccine Development in Leishmaniasis.Transboundary and emerging diseases · 2024Article
- The Therapeutic Effects of Curcumin-coated Gold Nanoparticle Against Leishmania Major Causative Agent of Zoonotic Cutaneous Leishmaniasis (ZCL): An In Vitro and In Vivo Study.Current microbiology · 2023Article
- Developments in Leishmaniasis diagnosis: A patent landscape from 2010 to 2022.PLOS global public health · 2023Article
- Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments.American journal of clinical dermatology · 2022Review
- An Overview on Leishmaniasis in Romania: Diagnosis and Therapeutics.Tropical medicine and infectious disease · 2022Review
- Geographic distribution of human leishmaniasis and phlebotomine sand flies in the State of Mato Grosso do Sul, Brazil.Parasites & vectors · 2022Article
- Next-generation sequencing technology for diagnosis and efficacy evaluation of a patient with visceral leishmaniasis: A case report.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Leishmaniasis is a set of complex and multifaceted syndromes, with different clinical manifestations, caused by different species of the genus Leishmania spp. that can be characterized by at least four syndromes: visceral leishmaniasis (VL, also known as kala-azar), post-kala-azar dermal leishmaniasis (PKDL), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis (MCL). Among the most serious clinical forms, VL stands out, which causes the death of around 59,000 people annually. Fast and accurate diagnosis in VL is essential to reduce the disease's morbidity and mortality. There are a large number of diagnostic tests for leishmaniasis, however they do cross-react with other protozoa and their sensitivity changes according to the clinical form of the disease. Thus, it is essential and necessary to provide a diagnosis that is sufficiently sensitive to detect asymptomatic infected individuals and specific to discriminate individuals with other infectious and parasitic diseases, thus enabling more accurate diagnostic tools than those currently used. In this context, the aim of this review is to summarize the conventional diagnostic tools and point out the new advances and strategies on visceral and cutaneous leishmaniasis diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.